Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 2011

View Archived Issues

Histamine H3 receptor antagonist JNJ-39220675 shows promise against alcoholism

Resminostat advances in phase I/II SHORE trial in colorectal cancer

BioMarin begins phase I/II trial of BMN-701 in late-onset Pompe's disease

Chinese scientists develop polycaprolactone-magnesium scaffold for bone repair

Masitinib mesilate prolongs survival of imatinib-naive subjects with advanced/metastatic GIST

Xybrex has analgesic activity in subjects undergoing iliac crest bone graft harvesting

Scientists identify satellite repeats in heterochromatin that are overexpressed in epithelial cancer

MycoVa demonstrates noninferiority to Loceryl in onychomycosis

Transcept resubmits Intermezzo NDA for insomnia to FDA

New activators of pyruvate kinase isozymes M1/M2 claimed

AstraZeneca presents new beta-secretase 1 inhibitors

Auspex Pharma patents new beta3-adrenoceptor modulators

New glucocorticoid receptor agonists discovered

FDA and Health Canada grant telaprevir priority review for HCV infection

Amicus Therapeutics announces milestones expected for 2011

Evotec and Takeda Cambridge join to identify GPCR and protease modulators

Geron begins phase II trial of imetelstat in essential thrombocythemia

Theraclone and Pfizer to codevelop antibodies against infectious disease and cancer targets

FDA sets PDUFA date for Adventrx's Exelbine NDA

NerBloc approved in Japan for treatment of cervical dystonia

CHMP issues positive opinion on European orphan drug status for darinaparsin in PTCL

Phase III data reported on levomilnacipran in major depressive disorder

New osteoporosis drug Edirol approved in Japan

Daiichi Sankyo's Alzheimer's disease treatment Memary approved in Japan

Health Canada approves once-daily antidepressant Oleptro

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...